nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Cladribine—multiple sclerosis	0.186	0.392	CbGbCtD
Leflunomide—ABCG2—Mitoxantrone—multiple sclerosis	0.135	0.286	CbGbCtD
Leflunomide—ABCG2—Dexamethasone—multiple sclerosis	0.0702	0.148	CbGbCtD
Leflunomide—ABCG2—Methotrexate—multiple sclerosis	0.0564	0.119	CbGbCtD
Leflunomide—CYP2C9—Dexamethasone—multiple sclerosis	0.0261	0.0551	CbGbCtD
Leflunomide—PTK2B—IL2-mediated signaling events—IFNG—multiple sclerosis	0.000598	0.00393	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL2—multiple sclerosis	0.000594	0.0039	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00059	0.00387	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00059	0.00387	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—MAPK1—multiple sclerosis	0.000589	0.00387	CbGpPWpGaD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000582	0.00382	CbGpPWpGaD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000582	0.00382	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—FAS—multiple sclerosis	0.000581	0.00382	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—HLA-DRB1—multiple sclerosis	0.000575	0.00378	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GPC5—multiple sclerosis	0.000569	0.00374	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000559	0.00368	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000559	0.00368	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—MX1—multiple sclerosis	0.000559	0.00367	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TYK2—multiple sclerosis	0.000551	0.00362	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—STAT3—multiple sclerosis	0.000547	0.00359	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DRA—multiple sclerosis	0.00054	0.00355	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—IL2—multiple sclerosis	0.000532	0.00349	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL2RA—multiple sclerosis	0.000521	0.00342	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NOD1—multiple sclerosis	0.00051	0.00335	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MYC—multiple sclerosis	0.000508	0.00334	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000506	0.00332	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MMP9—multiple sclerosis	0.000503	0.00331	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MAPK1—multiple sclerosis	0.000497	0.00327	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—BDNF—multiple sclerosis	0.000486	0.0032	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRF5—multiple sclerosis	0.000484	0.00318	CbGpPWpGaD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000478	0.00314	CbGpPWpGaD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000478	0.00314	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—RRM1—multiple sclerosis	0.000471	0.0031	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-G—multiple sclerosis	0.000463	0.00304	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRF8—multiple sclerosis	0.000463	0.00304	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—MAPK1—multiple sclerosis	0.000455	0.00299	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—STAT3—multiple sclerosis	0.000447	0.00294	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—STAT3—multiple sclerosis	0.000447	0.00294	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—MMP9—multiple sclerosis	0.000439	0.00289	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—SPP1—multiple sclerosis	0.000432	0.00284	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MYC—multiple sclerosis	0.000416	0.00273	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—MAPK1—multiple sclerosis	0.000413	0.00271	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MAPK1—multiple sclerosis	0.000407	0.00267	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MAPK1—multiple sclerosis	0.000407	0.00267	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—CD4—multiple sclerosis	0.000406	0.00267	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—STAT3—multiple sclerosis	0.000404	0.00265	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—multiple sclerosis	0.000393	0.00258	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—STAT3—multiple sclerosis	0.000386	0.00253	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CD4—multiple sclerosis	0.000384	0.00252	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TGFB1—multiple sclerosis	0.000374	0.00246	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DPB1—multiple sclerosis	0.00037	0.00243	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—TYK2—multiple sclerosis	0.00037	0.00243	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—TYK2—multiple sclerosis	0.000367	0.00241	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—MAPK1—multiple sclerosis	0.00036	0.00236	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—MAPK1—multiple sclerosis	0.00036	0.00236	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000356	0.00234	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL1B—multiple sclerosis	0.000355	0.00233	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—MMP9—multiple sclerosis	0.000353	0.00232	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IFNB1—multiple sclerosis	0.000353	0.00232	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—MAPK1—multiple sclerosis	0.000351	0.0023	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TNF—multiple sclerosis	0.000349	0.0023	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL6—multiple sclerosis	0.000349	0.00229	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—TYK2—multiple sclerosis	0.000349	0.00229	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—MAPK1—multiple sclerosis	0.000338	0.00222	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	0.000333	0.00219	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	0.000326	0.00214	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000318	0.00209	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—STAT3—multiple sclerosis	0.000314	0.00206	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—VCAM1—multiple sclerosis	0.00031	0.00203	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DQA1—multiple sclerosis	0.000309	0.00203	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL1B—multiple sclerosis	0.000307	0.00201	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL2—multiple sclerosis	0.000305	0.00201	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000304	0.002	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—P2RX7—multiple sclerosis	0.000301	0.00198	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000297	0.00195	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000297	0.00195	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000293	0.00193	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000293	0.00193	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DQB1—multiple sclerosis	0.000289	0.0019	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—IL6—multiple sclerosis	0.000282	0.00185	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000281	0.00184	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD226—multiple sclerosis	0.00028	0.00184	CbGpPWpGaD
Leflunomide—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000276	0.00182	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—TGFB1—multiple sclerosis	0.000276	0.00181	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-DRB4—multiple sclerosis	0.000271	0.00178	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—BCHE—multiple sclerosis	0.000271	0.00178	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—MAPK1—multiple sclerosis	0.00027	0.00178	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-B—multiple sclerosis	0.000259	0.0017	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—STAT3—multiple sclerosis	0.000257	0.00169	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CIITA—multiple sclerosis	0.000256	0.00168	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000254	0.00167	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000254	0.00167	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00025	0.00165	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00025	0.00165	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2RA—multiple sclerosis	0.000243	0.0016	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-A—multiple sclerosis	0.00024	0.00158	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL7—multiple sclerosis	0.000238	0.00156	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—C4A—multiple sclerosis	0.000238	0.00156	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—MAPK1—multiple sclerosis	0.000235	0.00155	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—MAPK1—multiple sclerosis	0.000234	0.00153	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000231	0.00152	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PDCD1—multiple sclerosis	0.000228	0.0015	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—LINGO1—multiple sclerosis	0.000225	0.00148	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL7R—multiple sclerosis	0.000224	0.00147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—MAPK1—multiple sclerosis	0.000222	0.00146	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DRB1—multiple sclerosis	0.00022	0.00144	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—ICAM1—multiple sclerosis	0.000211	0.00138	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	0.000209	0.00137	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL6—multiple sclerosis	0.000208	0.00136	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CBLB—multiple sclerosis	0.000205	0.00135	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—STAT3—multiple sclerosis	0.000204	0.00134	CbGpPWpGaD
Leflunomide—Malaise—Betamethasone—multiple sclerosis	0.000202	0.000539	CcSEcCtD
Leflunomide—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000201	0.000537	CcSEcCtD
Leflunomide—Vertigo—Betamethasone—multiple sclerosis	0.000201	0.000537	CcSEcCtD
Leflunomide—Vertigo—Dexamethasone—multiple sclerosis	0.000201	0.000537	CcSEcCtD
Leflunomide—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000201	0.000536	CcSEcCtD
Leflunomide—Arrhythmia—Prednisone—multiple sclerosis	0.0002	0.000534	CcSEcCtD
Leflunomide—Infection—Triamcinolone—multiple sclerosis	0.0002	0.000534	CcSEcCtD
Leflunomide—Infection—Methylprednisolone—multiple sclerosis	0.000199	0.000533	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—IL6—multiple sclerosis	0.000199	0.00131	CbGpPWpGaD
Leflunomide—Haematuria—Methotrexate—multiple sclerosis	0.000198	0.000531	CcSEcCtD
Leflunomide—Insomnia—Prednisolone—multiple sclerosis	0.000198	0.000529	CcSEcCtD
Leflunomide—Alopecia—Prednisone—multiple sclerosis	0.000198	0.000528	CcSEcCtD
Leflunomide—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000197	0.000526	CcSEcCtD
Leflunomide—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000197	0.000526	CcSEcCtD
Leflunomide—Epistaxis—Methotrexate—multiple sclerosis	0.000196	0.000525	CcSEcCtD
Leflunomide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000196	0.000525	CcSEcCtD
Leflunomide—Paraesthesia—Prednisolone—multiple sclerosis	0.000196	0.000525	CcSEcCtD
Leflunomide—Tachycardia—Triamcinolone—multiple sclerosis	0.000196	0.000524	CcSEcCtD
Leflunomide—Mental disorder—Prednisone—multiple sclerosis	0.000196	0.000524	CcSEcCtD
Leflunomide—Nausea—Azathioprine—multiple sclerosis	0.000196	0.000523	CcSEcCtD
Leflunomide—Tachycardia—Methylprednisolone—multiple sclerosis	0.000196	0.000523	CcSEcCtD
Leflunomide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000195	0.000521	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—TAGAP—multiple sclerosis	0.000195	0.00128	CbGpPWpGaD
Leflunomide—Malnutrition—Prednisone—multiple sclerosis	0.000195	0.00052	CcSEcCtD
Leflunomide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000194	0.000519	CcSEcCtD
Leflunomide—Agranulocytosis—Methotrexate—multiple sclerosis	0.000194	0.000519	CcSEcCtD
Leflunomide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000194	0.000518	CcSEcCtD
Leflunomide—Hypertension—Dexamethasone—multiple sclerosis	0.000193	0.000516	CcSEcCtD
Leflunomide—Hypertension—Betamethasone—multiple sclerosis	0.000193	0.000516	CcSEcCtD
Leflunomide—Asthenia—Mitoxantrone—multiple sclerosis	0.000191	0.000511	CcSEcCtD
Leflunomide—Myalgia—Betamethasone—multiple sclerosis	0.00019	0.000509	CcSEcCtD
Leflunomide—Myalgia—Dexamethasone—multiple sclerosis	0.00019	0.000509	CcSEcCtD
Leflunomide—Anxiety—Betamethasone—multiple sclerosis	0.00019	0.000507	CcSEcCtD
Leflunomide—Anxiety—Dexamethasone—multiple sclerosis	0.00019	0.000507	CcSEcCtD
Leflunomide—Discomfort—Dexamethasone—multiple sclerosis	0.000188	0.000503	CcSEcCtD
Leflunomide—Discomfort—Betamethasone—multiple sclerosis	0.000188	0.000503	CcSEcCtD
Leflunomide—Haemoglobin—Methotrexate—multiple sclerosis	0.000188	0.000502	CcSEcCtD
Leflunomide—Hypotension—Methylprednisolone—multiple sclerosis	0.000187	0.000501	CcSEcCtD
Leflunomide—Pain—Prednisolone—multiple sclerosis	0.000187	0.0005	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—multiple sclerosis	0.000187	0.000499	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—multiple sclerosis	0.000187	0.000499	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—STAT3—multiple sclerosis	0.000186	0.00122	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—MAPK1—multiple sclerosis	0.000186	0.00122	CbGpPWpGaD
Leflunomide—Pharyngitis—Methotrexate—multiple sclerosis	0.000185	0.000496	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000185	0.000493	CcSEcCtD
Leflunomide—Vision blurred—Prednisone—multiple sclerosis	0.000183	0.00049	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—multiple sclerosis	0.000183	0.00049	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000183	0.00049	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000183	0.000488	CcSEcCtD
Leflunomide—PTK2B—Immune System—MX1—multiple sclerosis	0.000182	0.0012	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000182	0.000488	CcSEcCtD
Leflunomide—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000182	0.000488	CcSEcCtD
Leflunomide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000182	0.000487	CcSEcCtD
Leflunomide—Insomnia—Triamcinolone—multiple sclerosis	0.000182	0.000486	CcSEcCtD
Leflunomide—Insomnia—Methylprednisolone—multiple sclerosis	0.000181	0.000485	CcSEcCtD
Leflunomide—Infection—Betamethasone—multiple sclerosis	0.000181	0.000484	CcSEcCtD
Leflunomide—Infection—Dexamethasone—multiple sclerosis	0.000181	0.000484	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—IL6—multiple sclerosis	0.000181	0.00119	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Prednisone—multiple sclerosis	0.000181	0.000483	CcSEcCtD
Leflunomide—Paraesthesia—Triamcinolone—multiple sclerosis	0.000181	0.000483	CcSEcCtD
Leflunomide—Feeling abnormal—Prednisolone—multiple sclerosis	0.00018	0.000482	CcSEcCtD
Leflunomide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00018	0.000481	CcSEcCtD
Leflunomide—Anaemia—Prednisone—multiple sclerosis	0.00018	0.000481	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—IL6—multiple sclerosis	0.00018	0.00118	CbGpPWpGaD
Leflunomide—Dyspnoea—Triamcinolone—multiple sclerosis	0.000179	0.000479	CcSEcCtD
Leflunomide—Nervous system disorder—Betamethasone—multiple sclerosis	0.000179	0.000478	CcSEcCtD
Leflunomide—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000179	0.000478	CcSEcCtD
Leflunomide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000179	0.000477	CcSEcCtD
Leflunomide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000179	0.000477	CcSEcCtD
Leflunomide—Tachycardia—Betamethasone—multiple sclerosis	0.000178	0.000476	CcSEcCtD
Leflunomide—Tachycardia—Dexamethasone—multiple sclerosis	0.000178	0.000476	CcSEcCtD
Leflunomide—Angioedema—Prednisone—multiple sclerosis	0.000178	0.000475	CcSEcCtD
Leflunomide—Dyspepsia—Triamcinolone—multiple sclerosis	0.000177	0.000473	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—multiple sclerosis	0.000177	0.000472	CcSEcCtD
Leflunomide—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000177	0.000472	CcSEcCtD
Leflunomide—PTK2B—Immune System—HLA-DRA—multiple sclerosis	0.000177	0.00116	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000176	0.000471	CcSEcCtD
Leflunomide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000176	0.000471	CcSEcCtD
Leflunomide—Malaise—Prednisone—multiple sclerosis	0.000176	0.000469	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000175	0.00115	CbGpPWpGaD
Leflunomide—Vertigo—Prednisone—multiple sclerosis	0.000175	0.000467	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—multiple sclerosis	0.000175	0.000467	CcSEcCtD
Leflunomide—Anorexia—Dexamethasone—multiple sclerosis	0.000174	0.000465	CcSEcCtD
Leflunomide—Anorexia—Betamethasone—multiple sclerosis	0.000174	0.000465	CcSEcCtD
Leflunomide—Urticaria—Prednisolone—multiple sclerosis	0.000174	0.000464	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—multiple sclerosis	0.000173	0.000464	CcSEcCtD
Leflunomide—Fatigue—Triamcinolone—multiple sclerosis	0.000173	0.000463	CcSEcCtD
Leflunomide—Fatigue—Methylprednisolone—multiple sclerosis	0.000173	0.000462	CcSEcCtD
Leflunomide—Pain—Triamcinolone—multiple sclerosis	0.000172	0.00046	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—TYK2—multiple sclerosis	0.000171	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—IL6—multiple sclerosis	0.000171	0.00112	CbGpPWpGaD
Leflunomide—Hypotension—Betamethasone—multiple sclerosis	0.00017	0.000456	CcSEcCtD
Leflunomide—Hypotension—Dexamethasone—multiple sclerosis	0.00017	0.000456	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—S1PR1—multiple sclerosis	0.00017	0.00112	CbGpPWpGaD
Leflunomide—Vomiting—Mitoxantrone—multiple sclerosis	0.000169	0.000453	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—MAPK1—multiple sclerosis	0.000169	0.00111	CbGpPWpGaD
Leflunomide—Immune system disorder—Methotrexate—multiple sclerosis	0.000169	0.000451	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000168	0.00045	CcSEcCtD
Leflunomide—Hypertension—Prednisone—multiple sclerosis	0.000168	0.000449	CcSEcCtD
Leflunomide—Rash—Mitoxantrone—multiple sclerosis	0.000168	0.000449	CcSEcCtD
Leflunomide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000168	0.000449	CcSEcCtD
Leflunomide—Chills—Methotrexate—multiple sclerosis	0.000168	0.000448	CcSEcCtD
Leflunomide—Headache—Mitoxantrone—multiple sclerosis	0.000167	0.000446	CcSEcCtD
Leflunomide—PTK2B—Immune System—NOD1—multiple sclerosis	0.000166	0.00109	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000166	0.000444	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000166	0.000444	CcSEcCtD
Leflunomide—Arthralgia—Prednisone—multiple sclerosis	0.000166	0.000443	CcSEcCtD
Leflunomide—Myalgia—Prednisone—multiple sclerosis	0.000166	0.000443	CcSEcCtD
Leflunomide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000166	0.000443	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GPC5—multiple sclerosis	0.000166	0.00109	CbGpPWpGaD
Leflunomide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000165	0.000442	CcSEcCtD
Leflunomide—Anxiety—Prednisone—multiple sclerosis	0.000165	0.000441	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—multiple sclerosis	0.000165	0.000441	CcSEcCtD
Leflunomide—Insomnia—Dexamethasone—multiple sclerosis	0.000165	0.000441	CcSEcCtD
Leflunomide—Insomnia—Betamethasone—multiple sclerosis	0.000165	0.000441	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000165	0.00044	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000164	0.000438	CcSEcCtD
Leflunomide—Paraesthesia—Dexamethasone—multiple sclerosis	0.000164	0.000438	CcSEcCtD
Leflunomide—Paraesthesia—Betamethasone—multiple sclerosis	0.000164	0.000438	CcSEcCtD
Leflunomide—Discomfort—Prednisone—multiple sclerosis	0.000164	0.000438	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—multiple sclerosis	0.000164	0.000438	CcSEcCtD
Leflunomide—DHODH—Metabolism—APOE—multiple sclerosis	0.000163	0.00107	CbGpPWpGaD
Leflunomide—Malnutrition—Methotrexate—multiple sclerosis	0.000163	0.000435	CcSEcCtD
Leflunomide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000161	0.000431	CcSEcCtD
Leflunomide—PTK2B—Immune System—MALT1—multiple sclerosis	0.000161	0.00106	CbGpPWpGaD
Leflunomide—Dyspepsia—Betamethasone—multiple sclerosis	0.000161	0.000429	CcSEcCtD
Leflunomide—Dyspepsia—Dexamethasone—multiple sclerosis	0.000161	0.000429	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IFNG—multiple sclerosis	0.00016	0.00105	CbGpPWpGaD
Leflunomide—Urticaria—Triamcinolone—multiple sclerosis	0.00016	0.000427	CcSEcCtD
Leflunomide—Urticaria—Methylprednisolone—multiple sclerosis	0.000159	0.000426	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—multiple sclerosis	0.000159	0.000426	CcSEcCtD
Leflunomide—Body temperature increased—Triamcinolone—multiple sclerosis	0.000159	0.000425	CcSEcCtD
Leflunomide—Anaphylactic shock—Prednisone—multiple sclerosis	0.000159	0.000425	CcSEcCtD
Leflunomide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000159	0.000424	CcSEcCtD
Leflunomide—Decreased appetite—Betamethasone—multiple sclerosis	0.000159	0.000424	CcSEcCtD
Leflunomide—Decreased appetite—Dexamethasone—multiple sclerosis	0.000159	0.000424	CcSEcCtD
Leflunomide—Nausea—Mitoxantrone—multiple sclerosis	0.000158	0.000423	CcSEcCtD
Leflunomide—PTK2B—Immune System—IRF5—multiple sclerosis	0.000158	0.00104	CbGpPWpGaD
Leflunomide—Infection—Prednisone—multiple sclerosis	0.000158	0.000422	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000157	0.000421	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000157	0.000421	CcSEcCtD
Leflunomide—Back pain—Methotrexate—multiple sclerosis	0.000157	0.000421	CcSEcCtD
Leflunomide—Fatigue—Dexamethasone—multiple sclerosis	0.000157	0.00042	CcSEcCtD
Leflunomide—Fatigue—Betamethasone—multiple sclerosis	0.000157	0.00042	CcSEcCtD
Leflunomide—Pain—Betamethasone—multiple sclerosis	0.000156	0.000417	CcSEcCtD
Leflunomide—Pain—Dexamethasone—multiple sclerosis	0.000156	0.000417	CcSEcCtD
Leflunomide—Nervous system disorder—Prednisone—multiple sclerosis	0.000156	0.000416	CcSEcCtD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000155	0.00102	CbGpPWpGaD
Leflunomide—Tachycardia—Prednisone—multiple sclerosis	0.000155	0.000414	CcSEcCtD
Leflunomide—Skin disorder—Prednisone—multiple sclerosis	0.000154	0.000412	CcSEcCtD
Leflunomide—Hyperhidrosis—Prednisone—multiple sclerosis	0.000154	0.00041	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—multiple sclerosis	0.000153	0.00041	CcSEcCtD
Leflunomide—Anorexia—Prednisone—multiple sclerosis	0.000151	0.000405	CcSEcCtD
Leflunomide—PTK2B—Immune System—IFIH1—multiple sclerosis	0.000151	0.000993	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IRF8—multiple sclerosis	0.000151	0.000993	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-G—multiple sclerosis	0.000151	0.000993	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000151	0.000403	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—multiple sclerosis	0.00015	0.000402	CcSEcCtD
Leflunomide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00015	0.000402	CcSEcCtD
Leflunomide—Feeling abnormal—Betamethasone—multiple sclerosis	0.00015	0.000402	CcSEcCtD
Leflunomide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000149	0.000399	CcSEcCtD
Leflunomide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000149	0.000399	CcSEcCtD
Leflunomide—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000148	0.000396	CcSEcCtD
Leflunomide—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000148	0.000395	CcSEcCtD
Leflunomide—Malaise—Methotrexate—multiple sclerosis	0.000147	0.000392	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—multiple sclerosis	0.000146	0.000391	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—multiple sclerosis	0.000146	0.000389	CcSEcCtD
Leflunomide—Urticaria—Dexamethasone—multiple sclerosis	0.000145	0.000387	CcSEcCtD
Leflunomide—Urticaria—Betamethasone—multiple sclerosis	0.000145	0.000387	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000145	0.000387	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—RGS1—multiple sclerosis	0.000145	0.000951	CbGpPWpGaD
Leflunomide—Dizziness—Prednisolone—multiple sclerosis	0.000145	0.000386	CcSEcCtD
Leflunomide—Asthenia—Triamcinolone—multiple sclerosis	0.000144	0.000386	CcSEcCtD
Leflunomide—Body temperature increased—Dexamethasone—multiple sclerosis	0.000144	0.000385	CcSEcCtD
Leflunomide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000144	0.000385	CcSEcCtD
Leflunomide—Abdominal pain—Betamethasone—multiple sclerosis	0.000144	0.000385	CcSEcCtD
Leflunomide—Body temperature increased—Betamethasone—multiple sclerosis	0.000144	0.000385	CcSEcCtD
Leflunomide—Asthenia—Methylprednisolone—multiple sclerosis	0.000144	0.000385	CcSEcCtD
Leflunomide—Insomnia—Prednisone—multiple sclerosis	0.000144	0.000384	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL1B—multiple sclerosis	0.000143	0.00094	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SRM—multiple sclerosis	0.000143	0.000938	CbGpPWpGaD
Leflunomide—Paraesthesia—Prednisone—multiple sclerosis	0.000143	0.000381	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2—multiple sclerosis	0.000143	0.000936	CbGpPWpGaD
Leflunomide—Pruritus—Triamcinolone—multiple sclerosis	0.000142	0.00038	CcSEcCtD
Leflunomide—Cough—Methotrexate—multiple sclerosis	0.000142	0.000379	CcSEcCtD
Leflunomide—Pruritus—Methylprednisolone—multiple sclerosis	0.000142	0.000379	CcSEcCtD
Leflunomide—PTK2B—Immune System—TNFAIP3—multiple sclerosis	0.000142	0.00093	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—POMC—multiple sclerosis	0.00014	0.000919	CbGpPWpGaD
Leflunomide—Dyspepsia—Prednisone—multiple sclerosis	0.00014	0.000374	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—multiple sclerosis	0.000138	0.00037	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—multiple sclerosis	0.000138	0.00037	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—multiple sclerosis	0.000138	0.00037	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000138	0.00091	CbGpPWpGaD
Leflunomide—Decreased appetite—Prednisone—multiple sclerosis	0.000138	0.000369	CcSEcCtD
Leflunomide—Rash—Prednisolone—multiple sclerosis	0.000138	0.000368	CcSEcCtD
Leflunomide—Dermatitis—Prednisolone—multiple sclerosis	0.000138	0.000368	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000138	0.000368	CcSEcCtD
Leflunomide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000137	0.000367	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GPR65—multiple sclerosis	0.000137	0.000901	CbGpPWpGaD
Leflunomide—Fatigue—Prednisone—multiple sclerosis	0.000137	0.000366	CcSEcCtD
Leflunomide—Headache—Prednisolone—multiple sclerosis	0.000137	0.000366	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—multiple sclerosis	0.000137	0.000366	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000137	0.000897	CbGpPWpGaD
Leflunomide—Constipation—Prednisone—multiple sclerosis	0.000136	0.000363	CcSEcCtD
Leflunomide—Dizziness—Triamcinolone—multiple sclerosis	0.000133	0.000355	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000133	0.000355	CcSEcCtD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000133	0.000872	CbGpPWpGaD
Leflunomide—Dizziness—Methylprednisolone—multiple sclerosis	0.000133	0.000355	CcSEcCtD
Leflunomide—Infection—Methotrexate—multiple sclerosis	0.000132	0.000353	CcSEcCtD
Leflunomide—Feeling abnormal—Prednisone—multiple sclerosis	0.000131	0.00035	CcSEcCtD
Leflunomide—Asthenia—Betamethasone—multiple sclerosis	0.000131	0.00035	CcSEcCtD
Leflunomide—Asthenia—Dexamethasone—multiple sclerosis	0.000131	0.00035	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—multiple sclerosis	0.00013	0.000348	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—multiple sclerosis	0.00013	0.000347	CcSEcCtD
Leflunomide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00013	0.000347	CcSEcCtD
Leflunomide—Nausea—Prednisolone—multiple sclerosis	0.00013	0.000347	CcSEcCtD
Leflunomide—Pruritus—Dexamethasone—multiple sclerosis	0.000129	0.000345	CcSEcCtD
Leflunomide—Pruritus—Betamethasone—multiple sclerosis	0.000129	0.000345	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—multiple sclerosis	0.000129	0.000345	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000128	0.000343	CcSEcCtD
Leflunomide—Vomiting—Triamcinolone—multiple sclerosis	0.000128	0.000342	CcSEcCtD
Leflunomide—DHODH—Metabolism—ALB—multiple sclerosis	0.000128	0.000838	CbGpPWpGaD
Leflunomide—Vomiting—Methylprednisolone—multiple sclerosis	0.000128	0.000341	CcSEcCtD
Leflunomide—PTK2B—Immune System—CD28—multiple sclerosis	0.000127	0.000837	CbGpPWpGaD
Leflunomide—Rash—Triamcinolone—multiple sclerosis	0.000127	0.000339	CcSEcCtD
Leflunomide—Dermatitis—Triamcinolone—multiple sclerosis	0.000127	0.000339	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—multiple sclerosis	0.000127	0.000338	CcSEcCtD
Leflunomide—Rash—Methylprednisolone—multiple sclerosis	0.000126	0.000338	CcSEcCtD
Leflunomide—Dermatitis—Methylprednisolone—multiple sclerosis	0.000126	0.000338	CcSEcCtD
Leflunomide—Urticaria—Prednisone—multiple sclerosis	0.000126	0.000337	CcSEcCtD
Leflunomide—Headache—Triamcinolone—multiple sclerosis	0.000126	0.000337	CcSEcCtD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000126	0.000827	CbGpPWpGaD
Leflunomide—Headache—Methylprednisolone—multiple sclerosis	0.000126	0.000336	CcSEcCtD
Leflunomide—Abdominal pain—Prednisone—multiple sclerosis	0.000126	0.000336	CcSEcCtD
Leflunomide—Body temperature increased—Prednisone—multiple sclerosis	0.000126	0.000336	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CCR1—multiple sclerosis	0.000125	0.000824	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL13—multiple sclerosis	0.000125	0.000824	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CCR2—multiple sclerosis	0.000125	0.000821	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTPRC—multiple sclerosis	0.000125	0.000821	CbGpPWpGaD
Leflunomide—Diarrhoea—Betamethasone—multiple sclerosis	0.000125	0.000334	CcSEcCtD
Leflunomide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000125	0.000334	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—multiple sclerosis	0.000124	0.000332	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000122	0.000804	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000122	0.0008	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000121	0.000797	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000121	0.000323	CcSEcCtD
Leflunomide—PTK2B—Immune System—HLA-DPB1—multiple sclerosis	0.000121	0.000794	CbGpPWpGaD
Leflunomide—Dizziness—Dexamethasone—multiple sclerosis	0.000121	0.000322	CcSEcCtD
Leflunomide—Dizziness—Betamethasone—multiple sclerosis	0.000121	0.000322	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—multiple sclerosis	0.00012	0.000321	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—STAT3—multiple sclerosis	0.00012	0.000788	CbGpPWpGaD
Leflunomide—Nausea—Triamcinolone—multiple sclerosis	0.000119	0.000319	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—multiple sclerosis	0.000119	0.000319	CcSEcCtD
Leflunomide—Nausea—Methylprednisolone—multiple sclerosis	0.000119	0.000318	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—multiple sclerosis	0.000118	0.000316	CcSEcCtD
Leflunomide—Hypersensitivity—Prednisone—multiple sclerosis	0.000117	0.000313	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—multiple sclerosis	0.000117	0.000312	CcSEcCtD
Leflunomide—PTK2B—Immune System—CD40—multiple sclerosis	0.000116	0.000764	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ITGA4—multiple sclerosis	0.000116	0.000764	CbGpPWpGaD
Leflunomide—Vomiting—Betamethasone—multiple sclerosis	0.000116	0.00031	CcSEcCtD
Leflunomide—Vomiting—Dexamethasone—multiple sclerosis	0.000116	0.00031	CcSEcCtD
Leflunomide—Decreased appetite—Methotrexate—multiple sclerosis	0.000115	0.000308	CcSEcCtD
Leflunomide—PTK2B—Immune System—IFNB1—multiple sclerosis	0.000115	0.000758	CbGpPWpGaD
Leflunomide—Rash—Dexamethasone—multiple sclerosis	0.000115	0.000307	CcSEcCtD
Leflunomide—Rash—Betamethasone—multiple sclerosis	0.000115	0.000307	CcSEcCtD
Leflunomide—Dermatitis—Betamethasone—multiple sclerosis	0.000115	0.000307	CcSEcCtD
Leflunomide—Dermatitis—Dexamethasone—multiple sclerosis	0.000115	0.000307	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000115	0.000306	CcSEcCtD
Leflunomide—PTK2B—Immune System—CTLA4—multiple sclerosis	0.000115	0.000753	CbGpPWpGaD
Leflunomide—Fatigue—Methotrexate—multiple sclerosis	0.000114	0.000306	CcSEcCtD
Leflunomide—Headache—Dexamethasone—multiple sclerosis	0.000114	0.000305	CcSEcCtD
Leflunomide—Headache—Betamethasone—multiple sclerosis	0.000114	0.000305	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000114	0.00075	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000114	0.00075	CbGpPWpGaD
Leflunomide—Asthenia—Prednisone—multiple sclerosis	0.000114	0.000305	CcSEcCtD
Leflunomide—Pain—Methotrexate—multiple sclerosis	0.000114	0.000303	CcSEcCtD
Leflunomide—Pruritus—Prednisone—multiple sclerosis	0.000112	0.0003	CcSEcCtD
Leflunomide—Feeling abnormal—Methotrexate—multiple sclerosis	0.000109	0.000292	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—MAPK1—multiple sclerosis	0.000109	0.000716	CbGpPWpGaD
Leflunomide—Diarrhoea—Prednisone—multiple sclerosis	0.000109	0.000291	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000109	0.00029	CcSEcCtD
Leflunomide—Nausea—Betamethasone—multiple sclerosis	0.000108	0.00029	CcSEcCtD
Leflunomide—Nausea—Dexamethasone—multiple sclerosis	0.000108	0.00029	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000108	0.000707	CbGpPWpGaD
Leflunomide—Urticaria—Methotrexate—multiple sclerosis	0.000105	0.000282	CcSEcCtD
Leflunomide—Dizziness—Prednisone—multiple sclerosis	0.000105	0.000281	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—multiple sclerosis	0.000105	0.000281	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—multiple sclerosis	0.000105	0.000281	CcSEcCtD
Leflunomide—PTK2B—Immune System—VCAM1—multiple sclerosis	0.000101	0.000664	CbGpPWpGaD
Leflunomide—Vomiting—Prednisone—multiple sclerosis	0.000101	0.00027	CcSEcCtD
Leflunomide—PTK2B—Immune System—HLA-DQA1—multiple sclerosis	0.000101	0.000663	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP24A1—multiple sclerosis	0.000101	0.000661	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP27B1—multiple sclerosis	0.000101	0.000661	CbGpPWpGaD
Leflunomide—Rash—Prednisone—multiple sclerosis	0.0001	0.000268	CcSEcCtD
Leflunomide—Dermatitis—Prednisone—multiple sclerosis	0.0001	0.000267	CcSEcCtD
Leflunomide—Headache—Prednisone—multiple sclerosis	9.95e-05	0.000266	CcSEcCtD
Leflunomide—Hypersensitivity—Methotrexate—multiple sclerosis	9.78e-05	0.000261	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	9.75e-05	0.000641	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	9.75e-05	0.000641	CbGpPWpGaD
Leflunomide—Asthenia—Methotrexate—multiple sclerosis	9.53e-05	0.000255	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	9.49e-05	0.000623	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	9.46e-05	0.000622	CbGpPWpGaD
Leflunomide—Nausea—Prednisone—multiple sclerosis	9.44e-05	0.000252	CcSEcCtD
Leflunomide—PTK2B—Immune System—HLA-DQB1—multiple sclerosis	9.43e-05	0.00062	CbGpPWpGaD
Leflunomide—Pruritus—Methotrexate—multiple sclerosis	9.39e-05	0.000251	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	9.28e-05	0.00061	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPC5—multiple sclerosis	9.2e-05	0.000605	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD86—multiple sclerosis	9.09e-05	0.000597	CbGpPWpGaD
Leflunomide—Diarrhoea—Methotrexate—multiple sclerosis	9.08e-05	0.000243	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CCL3—multiple sclerosis	8.94e-05	0.000587	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD40LG—multiple sclerosis	8.91e-05	0.000585	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	8.84e-05	0.00058	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	8.84e-05	0.00058	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—multiple sclerosis	8.81e-05	0.000579	CbGpPWpGaD
Leflunomide—Dizziness—Methotrexate—multiple sclerosis	8.78e-05	0.000235	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PTGER4—multiple sclerosis	8.6e-05	0.000565	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-B—multiple sclerosis	8.47e-05	0.000557	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PGR—multiple sclerosis	8.47e-05	0.000557	CbGpPWpGaD
Leflunomide—Vomiting—Methotrexate—multiple sclerosis	8.44e-05	0.000226	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6—multiple sclerosis	8.38e-05	0.00055	CbGpPWpGaD
Leflunomide—Rash—Methotrexate—multiple sclerosis	8.37e-05	0.000224	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—multiple sclerosis	8.36e-05	0.000224	CcSEcCtD
Leflunomide—Headache—Methotrexate—multiple sclerosis	8.32e-05	0.000222	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CXCR3—multiple sclerosis	8.31e-05	0.000546	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CD28—multiple sclerosis	8.23e-05	0.000541	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCR2—multiple sclerosis	8.08e-05	0.000531	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2RA—multiple sclerosis	7.94e-05	0.000522	CbGpPWpGaD
Leflunomide—Nausea—Methotrexate—multiple sclerosis	7.89e-05	0.000211	CcSEcCtD
Leflunomide—PTK2B—Immune System—HLA-A—multiple sclerosis	7.85e-05	0.000516	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—RRM1—multiple sclerosis	7.63e-05	0.000501	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CNR1—multiple sclerosis	7.46e-05	0.00049	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SRM—multiple sclerosis	7.21e-05	0.000474	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR4—multiple sclerosis	7.18e-05	0.000472	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-DRB1—multiple sclerosis	7.17e-05	0.000471	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ICAM1—multiple sclerosis	6.89e-05	0.000452	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL10—multiple sclerosis	6.72e-05	0.000441	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	6.69e-05	0.000439	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD80—multiple sclerosis	6.63e-05	0.000435	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SRM—multiple sclerosis	6.16e-05	0.000405	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CD86—multiple sclerosis	5.87e-05	0.000386	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCL5—multiple sclerosis	5.78e-05	0.00038	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—POMC—multiple sclerosis	5.71e-05	0.000375	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TYK2—multiple sclerosis	5.59e-05	0.000368	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SPP1—multiple sclerosis	5.36e-05	0.000352	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNG—multiple sclerosis	5.24e-05	0.000344	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCR5—multiple sclerosis	5.21e-05	0.000342	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2RA—multiple sclerosis	5.13e-05	0.000337	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	5.08e-05	0.000334	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	5.08e-05	0.000334	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD4—multiple sclerosis	5.06e-05	0.000332	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.97e-05	0.000326	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APOE—multiple sclerosis	4.74e-05	0.000311	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1B—multiple sclerosis	4.67e-05	0.000307	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—multiple sclerosis	4.66e-05	0.000306	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPC5—multiple sclerosis	4.65e-05	0.000305	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	4.41e-05	0.000289	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—BCHE—multiple sclerosis	4.38e-05	0.000288	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	4.34e-05	0.000285	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	4.34e-05	0.000285	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CD80—multiple sclerosis	4.29e-05	0.000282	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.25e-05	0.000279	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—POMC—multiple sclerosis	4.07e-05	0.000267	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCL2—multiple sclerosis	3.98e-05	0.000262	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPC5—multiple sclerosis	3.97e-05	0.000261	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—multiple sclerosis	3.92e-05	0.000257	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RRM1—multiple sclerosis	3.85e-05	0.000253	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TYK2—multiple sclerosis	3.62e-05	0.000238	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK1—multiple sclerosis	3.56e-05	0.000234	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RRM1—multiple sclerosis	3.29e-05	0.000216	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—multiple sclerosis	3.01e-05	0.000198	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.99e-05	0.000196	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—multiple sclerosis	2.85e-05	0.000187	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—multiple sclerosis	2.74e-05	0.00018	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOE—multiple sclerosis	2.64e-05	0.000173	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.57e-05	0.000169	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.55e-05	0.000168	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—multiple sclerosis	2.53e-05	0.000166	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—multiple sclerosis	2.35e-05	0.000155	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—multiple sclerosis	2.35e-05	0.000154	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.34e-05	0.000154	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK1—multiple sclerosis	2.3e-05	0.000151	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—POMC—multiple sclerosis	2.26e-05	0.000149	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BCHE—multiple sclerosis	2.21e-05	0.000145	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.19e-05	0.000144	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—multiple sclerosis	2.06e-05	0.000136	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2e-05	0.000131	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BCHE—multiple sclerosis	1.89e-05	0.000124	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—multiple sclerosis	1.77e-05	0.000116	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOE—multiple sclerosis	1.33e-05	8.74e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—POMC—multiple sclerosis	1.14e-05	7.51e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOE—multiple sclerosis	1.14e-05	7.47e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—multiple sclerosis	1.04e-05	6.85e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—POMC—multiple sclerosis	9.77e-06	6.42e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—multiple sclerosis	8.91e-06	5.85e-05	CbGpPWpGaD
